| Mrs Angela Ruth Jackson-lopez, M D | |
|
1821 E High St, Springfield, OH 45505-1225 | |
| (937) 323-7340 | |
| (937) 323-3363 |
| Full Name | Mrs Angela Ruth Jackson-lopez |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 24 Years |
| Location | 1821 E High St, Springfield, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841297835 | NPI | - | NPPES |
| 2525486 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 35084279 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohio Valley Surgical Hospital | Springfield, OH | Hospital |
| Springfield Regional Medical Center | Springfield, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians And Surgeons For Women Inc | 4789643222 | 3 |
News Archive
The UK Medicines and Healthcare products Regulatory Agency advised that patients with certain artificial hips need annual tests to check for metal ions and MRIs if they show symptoms. The new guidelines follow reports from doctors of swelling and tissue damage in some patients with metal-on-metal hip implants. The update applies to those in Britain with a hip replacement with a head diameter of 36 millimetres or more. The MHRA said on Tuesday that around 49,000 UK patients with large-head hip implants out of 65,000 with all-metal hips were in a high-risk category.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.
› Verified 2 days ago
| Entity Name | Physicians & Surgeons For Women Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508987629 PECOS PAC ID: 4789643222 Enrollment ID: O20041008000868 |
News Archive
The UK Medicines and Healthcare products Regulatory Agency advised that patients with certain artificial hips need annual tests to check for metal ions and MRIs if they show symptoms. The new guidelines follow reports from doctors of swelling and tissue damage in some patients with metal-on-metal hip implants. The update applies to those in Britain with a hip replacement with a head diameter of 36 millimetres or more. The MHRA said on Tuesday that around 49,000 UK patients with large-head hip implants out of 65,000 with all-metal hips were in a high-risk category.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Angela Ruth Jackson-lopez, M D 1821 E High St, Springfield, OH 45505-1225 Ph: (937) 323-7340 | Mrs Angela Ruth Jackson-lopez, M D 1821 E High St, Springfield, OH 45505-1225 Ph: (937) 323-7340 |
News Archive
The UK Medicines and Healthcare products Regulatory Agency advised that patients with certain artificial hips need annual tests to check for metal ions and MRIs if they show symptoms. The new guidelines follow reports from doctors of swelling and tissue damage in some patients with metal-on-metal hip implants. The update applies to those in Britain with a hip replacement with a head diameter of 36 millimetres or more. The MHRA said on Tuesday that around 49,000 UK patients with large-head hip implants out of 65,000 with all-metal hips were in a high-risk category.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.
› Verified 2 days ago
Lynne A Eaton, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 100 Medical Center Dr, Springfield, OH 45504 Phone: 937-523-4147 Fax: 937-523-4952 | |
Dr. Lisa M Delong, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1821 E High St, Springfield, OH 45505 Phone: 937-323-7340 Fax: 937-323-3363 | |
Christy Campbell Smalley, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1108 Vester Ave, Springfield, OH 45503 Phone: 937-399-7100 Fax: 937-399-7355 | |
Dr. Curtis J Orr, MD Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 1108 Vester Ave, Springfield, OH 45503 Phone: 937-399-7100 Fax: 937-399-7355 | |
Dr. Rodney E. Batie, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1835 E High St, Springfield, OH 45505 Phone: 937-323-9242 Fax: 937-322-5252 | |
Dr. Richard Gregory Mcneely, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1108 Vester Ave, Springfield, OH 45503 Phone: 937-399-7100 Fax: 937-399-7355 | |
Steven Todd Patterson, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1108 Vester Ave, Springfield, OH 45503 Phone: 937-399-7100 Fax: 937-399-7355 |